PMID- 35088444
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20231105
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 94
IP  - 5
DP  - 2022 May
TI  - The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 
      outpatients: A systematic review and meta-analysis of randomized controlled 
      trials.
PG  - 2222-2229
LID - 10.1002/jmv.27623 [doi]
AB  - To assess the clinical efficacy and safety of neutralizing monoclonal antibodies 
      (mABs) for outpatients with coronavirus disease 2019 (COVID-19). PubMed, Embase, 
      Web of Science, Cochrane Library, ClinicalTrials.gov, and World Health 
      Organization International Clinical Trials Registry Platform (ICTRP) databases 
      were searched from inception to July 19, 2021. Only randomized controlled trials 
      (RCTs) that assessed the clinical efficacy and safety of neutralizing mABs in the 
      treatment of COVID-19 outpatients were included. The Cochrane risk-of-bias tool 
      was used to assess the quality of the included RCTs. The primary outcome was the 
      risk of COVID-19-related hospitalization or emergency department (ED) visits. The 
      secondary outcomes were the risk of death and adverse events (AEs). Five articles 
      were included, in which 3309 patients received neutralizing mAB and 2397 patients 
      received a placebo. A significantly lower rate of hospitalization or ED visits 
      was observed among patients who received neutralizing mABs than those who 
      received a placebo (1.7% vs. 6.5%, odds ratios (OR): 0.26; 95% confidence 
      interval (CI): 0.19-0.36; I(2)  = 0%). In addition, the rate of hospitalization 
      was significantly lower in the patients who received neutralizing mABs than in 
      the control group (OR: 0.24; 95% CI: 0.17-0.34; I(2)  = 0%). The mortality rate 
      was also significantly lower in the patients who received neutralizing mABs than 
      in the control group (OR: 0.16; 95% CI: 0.05-0.58; I(2)  = 3%). Neutralizing mABs 
      were associated with a similar risk of any AE (OR: 0.81; 95% CI: 0.64-1.01; I(2) 
       = 52%) and a lower risk of serious AEs (OR: 0.37; 97% CI: 0.19-0.72; I(2) 
       = 45%) compared with a placebo. Neutralizing mABs can help reduce the risk of 
      hospitalization or ED visits in COVID-19 outpatients. For these patients, 
      neutralizing mABs are safe and not associated with a higher risk of AEs than a 
      placebo.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Lin, Wei-Ting
AU  - Lin WT
AD  - Department of Orthopedic, Chi Mei Medical Center, Tainan, Taiwan.
FAU - Hung, Shun-Hsing
AU  - Hung SH
AD  - Department of Surgery, Division of Urology, Chi-Mei Hospital, Chia Li, Tainan, 
      Taiwan.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AUID- ORCID: 0000-0002-6334-2388
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan, Taiwan.
FAU - Wang, Cheng-Yi
AU  - Wang CY
AD  - Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, 
      College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
FAU - Chen, Chao-Hsien
AU  - Chen CH
AUID- ORCID: 0000-0002-2176-3504
AD  - Department of Internal Medicine, Division of Pulmonary, MacKay Memorial Hospital, 
      Taipei, Taiwan.
AD  - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220207
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Neutralizing/therapeutic use
MH  - Humans
MH  - Outpatients
MH  - Randomized Controlled Trials as Topic
MH  - *COVID-19 Drug Treatment
PMC - PMC9015482
OTO - NOTNLM
OT  - COVID-19
OT  - emergency department
OT  - hospitalization
OT  - neutralizing monoclonal antibody
OT  - safety
EDAT- 2022/01/29 06:00
MHDA- 2022/03/24 06:00
CRDT- 2022/01/28 05:57
PHST- 2022/01/19 00:00 [revised]
PHST- 2021/12/15 00:00 [received]
PHST- 2022/01/21 00:00 [accepted]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2022/01/28 05:57 [entrez]
AID - 10.1002/jmv.27623 [doi]
PST - ppublish
SO  - J Med Virol. 2022 May;94(5):2222-2229. doi: 10.1002/jmv.27623. Epub 2022 Feb 7.